Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.62 (
caspase-9
)
7,507
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ceramide can be converted into sphingomyelin by sphingomyelin synthases (SMS) 1 and 2. In this study, we show that in human leukemia Jurkat cells, which express mainly
SMS1
, Fas ligand (FasL) treatment inhibited SMS activity in a dose- and time-dependent manner before nuclear fragmentation. The SMS inhibition elicited by FasL (1) was abrogated by benzyloxycarbonyl valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone (zVAD-fmk), a broad-spectrum caspase inhibitor; (2) did not occur in caspase-8-deficient cells and (3) was not affected in
caspase-9
-deficient cells. Western blot experiments showed
SMS1
cleavage in a caspase-dependent manner upon FasL treatment. In a cell-free system, caspase-2, -7, -8 and -9, but not caspase-3 and -10, cleaved
SMS1
. In HeLa cells,
SMS1
was Golgi localized and relocated throughout the cytoplasm in cells exhibiting an early apoptotic phenotype on FasL treatment. zVAD-fmk prevented FasL-induced
SMS1
relocation. Thus, FasL-mediated
SMS1
inhibition and relocation depend on caspase activation and likely represent proximal events in Fas signaling. FasL-induced ceramide production and cell death were enhanced in cells stably expressing an siRNA against
SMS1
. Conversely, in cells stably overexpressing
SMS1
, FasL neither increased ceramide generation nor efficiently induced cell death. Altogether, our data show that
SMS1
is a novel caspase target that is functionally involved in the regulation of FasL-induced apoptosis.
...
PMID:Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. 1977 94
Sphingomyelin synthases 1 and 2 convert the anti-oncometabolite ceramide to sphingomyelin, the most abundant sphingolipid in plasma membrane. CD95L-induced ceramide increase is associated with the caspase-dependent inhibition of sphingomyelin synthesis, which enhances the mitochondrial route to apoptosis. Knocking down sphingomyelin synthase 1 or inhibiting sphingomyelin synthesis facilitates ceramide accumulation, cytochrome c release from mitochondria, and
caspase-9
activation in cancer cell upon CD95L treatment. Here, we describe a method to monitor in situ
sphingomyelin synthase
activity changes triggered by CD95L.
...
PMID:Method to Measure Sphingomyelin Synthase Activity Changes in Response to CD95L. 2807 95